Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia A meta-analysis and systematic review

被引:94
|
作者
Wei, Jing [1 ]
Zhang, Weiyuan [1 ]
Feng, Limin [2 ]
Gao, Wanli [2 ]
机构
[1] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Tian Tan Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
atypical complex hyperplasia; early endometrial cancer; fertility-sparing treatments; meta-analysis; systematic review; YOUNG-WOMEN; MEDROXYPROGESTERONE ACETATE; CONSERVATIVE TREATMENT; REPRODUCTIVE OUTCOMES; PROGESTOGEN TREATMENT; PRESERVING TREATMENT; ORAL PROGESTIN; PHASE-II; MANAGEMENT; ADENOCARCINOMA;
D O I
10.1097/MD.0000000000008034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There are some fertility-sparing treatments in patients with early endometrial cancer (EEC) or atypical complex hyperplasia (ACH), and the objective is to compare them by evaluating the oncologic and reproductive outcomes. Methods: We searched the published literature using Medline, Cochrane, EMBASE, and Google Scholar databases up to January 3, 2017, with various combinations of keywords fertility-sparing treatments, progesterone, progestin, intrauterine devices, early endometrial cancer, and atypical complex hyperplasia. The primary endpoint is the complete response (CR) rate, and the secondary endpoints are the partial response (PR) rate, relapse rate (RR), pregnancy rate, and live birth rate. Results: Twenty-eight studies containing 1038 women with EEC or ACH were included for review and meta-analysis. The results demonstrated that women with EEC or ACH managed with progestin had a pooled CR rate of 71% (95% confidence interval [CI]: 63-77%). The pooled pregnancy outcomes showed that 34% of women taking progestin treatment for EEC or ACH became pregnant (95% CI: 30-38%); however, only 20% of them delivered live newborns. The pooled CR rate for women using intrauterine device (IUD) was 76% (95% CI: 67-83%), and pooled RR was 9% (95% CI: 5-17%). The pregnancy rate for women whom underwent IUD was 18% (95% CI: 7-37%), and 14% of them delivered live newborns. In patients using progestin plus IUD, the pooled CR rate was 87% (95% CI: 75-93%); among those patients, 40% became pregnant (95% CI: 20-63%), and 35% delivered live newborns. There is no publication bias for the CR rate. Conclusion: For patients with EEC and ACH, treatments with progestin, with or without IUD, or IUD alone can reach good CR rate; however, the pregnancy outcomes might be worse in patients treated with IUD alone. Further randomized-controlled studies are warranted to find out a better solution.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis
    De Rocco, Silvia
    Buca, Danilo
    Oronzii, Ludovica
    Petrillo, Marco
    Fanfani, Francesco
    Nappi, Luigi
    Liberati, Marco
    D'Antonio, Francesco
    Scambia, Giovanni
    Leombroni, Martina
    Dessole, Margherita
    Lucidi, Alessandro
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2022, 273 : 90 - 97
  • [2] A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma
    Guillon, Sarah
    Popescu, Nathalie
    Phelippeau, Juliette
    Koskas, Martin
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2019, 146 (03) : 277 - 288
  • [3] Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol
    Maria-Eulalia Fernandez-Montoli
    Jordi Sabadell
    Nayanar-Adela Contreras-Perez
    [J]. Advances in Therapy, 2021, 38 : 2717 - 2731
  • [4] Fertility-sparing treatment in MSI-H/MMRd endometrial carcinoma or atypical endometrial hyperplasia: A systematic review and meta-analysis
    Zhang, Tianyu
    Zhang, Xinyue
    Peng, Peng
    Yang, Jiaxin
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2024, 302 : 177 - 183
  • [5] Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol
    Fernandez-Montoli, Maria-Eulalia
    Sabadell, Jordi
    Contreras-Perez, Nayanar-Adela
    [J]. ADVANCES IN THERAPY, 2021, 38 (05) : 2717 - 2731
  • [6] Fertility-sparing management of endometrial cancer and atypical hyperplasia
    Gonthier, C.
    Trefoux-Bourdet, A.
    Luton, D.
    Koskas, M.
    [J]. GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2017, 45 (02): : 112 - 118
  • [7] Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity
    Chen, Junyu
    Cao, Dongyan
    Yang, Jiaxin
    Yu, Mei
    Zhou, Huimei
    Cheng, Ninghai
    Wang, Jinhui
    Zhang, Ying
    Peng, Peng
    Shen, Keng
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis
    Koskas, Martin
    Uzan, Jennifer
    Luton, Dominique
    Rouzier, Roman
    Darai, Emile
    [J]. FERTILITY AND STERILITY, 2014, 101 (03) : 785 - +
  • [9] The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option
    Gadducci, Angiolo
    Spirito, Nicoletta
    Baroni, Elena
    Tana, Roberta
    Genazzani, Andrea Riccardo
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (10) : 683 - 691
  • [10] Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis
    Gallos, Ioannis D.
    Yap, Jason
    Rajkhowa, Madhurima
    Luesley, David M.
    Coomarasamy, Arri
    Gupta, Janesh K.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (04)